Einzeltreffer — DigiBib

Background: Breast cancer residual disease assessment in early-stage patients has been challenging and lacks routine identification of adjuvant therapy benefit and objective measure of therapy success. Liquid biopsy assays targeting tumor-derived entities are investigated for minimal residual disease detection, yet perform low in clinical sensitivity. We propose the detection of CD44-related systemic inflammation for the assessment of residual cancer.

Methods: Circulating CD44+/CD45- rare cells from healthy, noncancer- and cancer-afflicted donors were enriched by CD45 depletion and analyzed by immuno-fluorescence microscopy. CD44+ rare cell subtyping was based on cytological feature analysis and referred to as morphological index. AUC analysis was employed for identification of the most cancer-specific CD44+ subtype.

Results: The EpCam-/CD44+/CD24-/CD71-/CD45-/DNA+ phenotype alludes to a distinct cell type and was found frequently at concentrations below 5 cells per 5 mL in healthy donors. Marker elevation by at least 5 × on average was observed in all afflicted cohorts. The positive predicted value for the prediction of malignancy-associated systemic inflammation of a CD44+ rare cell subtype with a higher morphological index was 87%. An outlook for the frequency of sustained inflammation in residual cancer may be given to measure 78%.

Conclusion: The CD44+ rare cell and subtype denotes improvement in detection of residual cancer disease and may provide an objective and alternative measure of disease burden in early-stage breast cancer.

Titel:	New inflammatory indicators for cell-based liquid biopsy: association of the circulating CD44+/CD24- non-hematopoietic rare cell phenotype with breast cancer residual disease.
Autor/in / Beteiligte Person:	Schreier, S ; Budchart, P ; Borwornpinyo, S ; Arpornwirat, W ; Lertsithichai, P ; Chirappapha, P ; Triampo, W
Link:	Full Text Finder (Volltext)
Zeitschrift:	Journal of cancer research and clinical oncology, Jg. 149 (2023-07-01), Heft 8, S. 4347-4358
Veröffentlichung:	Berlin ; New York : Springer-Verlag., 2023
Medientyp:	academicJournal
ISSN:	1432-1335 (electronic)
DOI:	10.1007/s00432-022-04330-5
Schlagwort:	Humans Neoplasm, Residual pathology Phenotype Liquid Biopsy CD24 Antigen Neoplastic Stem Cells metabolism Hyaluronan Receptors metabolism Inflammation metabolism
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [J Cancer Res Clin Oncol] 2023 Jul; Vol. 149 (8), pp. 4347-4358. <i>Date of Electronic Publication: </i>2022 Sep 13. MeSH Terms: Hyaluronan Receptors* / metabolism ; Inflammation* / metabolism ; Humans ; Neoplasm, Residual / pathology ; Phenotype ; Liquid Biopsy ; CD24 Antigen ; Neoplastic Stem Cells / metabolism References: Aceto N (2019) Fluctuating numbers of circulating tumor cells in cancer patients and the meaning of zero counts. Oncotarget 10(28):2658. (PMID: 311058676505632) ; Akhter MZ et al (2018) Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM+ CD45+ phenotype. Oncogene 37:2089–2103. (PMID: 29379166) ; Allard WJ et al (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904. (PMID: 15501967) ; Bhakdi SC et al (2019) Accuracy of tumour-associated circulating endothelial cells as a screening biomarker for clinically significant prostate cancer. Cancers 11:1064. (PMID: 313576516721410) ; Bradley R et al (2021) Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol 22(8):1139–1150. ; Brau S et al (1999) Tumor–antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer 84(1):1–5. ; Burger D, Touyz RM (2012) Cellular biomarkers of endothelial health: microparticles, endothelial progenitor cells, and circulating endothelial cells. J Am Soc Hypertens 6(2):85–99. (PMID: 22321962) ; Coates AS et al (2015) Tailoring therapies—improving the management of early breast cancer: st gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol 26(8):1533–1546. (PMID: 259398964511219) ; Cole SW (2009) Chronic inflammation and breast cancer recurrence. J Clin Oncol off J Am Soc Clin Oncol 27:3418. ; Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Gusterson B, Neville AM (1999) Role of immunohistochemical detection of lymph-node metastases in management of breast cancer International Breast Cancer Study Group. Lancet 354:896–900. (PMID: 10489948) ; Galland S, Stamenkovic I (2020) Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression. J Pathol 250(5):555–572. (PMID: 31608444) ; Gamucci T et al (2013) Recurrence risk in small, node-negative, early breast cancer: a multicenter retrospective analysis. J Cancer Res Clin Oncol 139(5):853–860. (PMID: 234116863625404) ; Gardner MJ et al (1995) Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 91:229–234. (PMID: 7539337) ; Geeurickx E, Hendrix An (2020) Targets, pitfalls and reference materials for liquid biopsy tests in cancer diagnostics. Mol Aspects Med 72:100828. (PMID: 31711714) ; George J et al (2004) Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur Heart J 25:1003–1008. (PMID: 15191769) ; Goodison S, Urquidi V, Tarin D (1999) CD44 cell adhesion molecules. Mol Pathol 52(4):189–196. https://doi.org/10.1136/mp.52.4.189.PMC395698.PMID10694938. (PMID: 10.1136/mp.52.4.189.PMC395698.PMID1069493810694938395698) ; Herrera MB et al (2007) Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int 72(4):430–441. (PMID: 17507906) ; Hida K, Klagsbrun M (2005) A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 65:2507–2510. (PMID: 15805239) ; Johnson P, Ruffell B (2009) CD44 and its role in inflammation and inflammatory diseases. Inflamm Allergy-Drug Targets (formerly Current Drug Targets-Inflammation & Allergy) (discontinued) 8:208–220. ; Lin AY et al (2021) Identification and comprehensive co-detection of necrotic and viable aneuploid cancer cells in peripheral blood. Cancers 13:5108. (PMID: 346802568534250) ; Meng S et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10(24):8152–8162. (PMID: 15623589) ; Murray NP et al (2021) Immune dysfunction as measured by the systemic immune-inflammation index is associated with the sub-type of minimal residual disease and outcome in stage II colon cancer treated with surgery alone. Asian Pac J Cancer Prev APJCP 22:2391. (PMID: 34452551) ; Nikitovic D et al (2015) Cancer microenvironment and inflammation: role of hyaluronan. Front Immunol 6:169. (PMID: 259268344396412) ; Pachmann K (2015) Current and potential use of MAINTRAC method for cancer diagnosis and prediction of metastasis. Expert Rev Mol Diagn 15(5):597–605. (PMID: 25843106) ; Pan H et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836–1846. (PMID: 291174985734609) ; Pantel K, Alix-Panabières C (2019) Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol 16(7):409–424. (PMID: 30796368) ; Pantel K, Deneve E, Nocca D et al (2012) Circulating epithelial cells in patients with benign colon diseases. Clin Chem 58:936–940. (PMID: 22205690) ; Papadaki MA et al (2020) "Clinical relevance of immune checkpoints on circulating tumor cells in breast cancer. Cancers 12:376. (PMID: 320413537072621) ; Park CK et al (2020) Circulating tumor cell as a predictive marker for immunotherapy in advnaced non-small cell lung cancer. Cancer Res 80:5373–5373. ; Parsons HA et al (2020) "Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. Clin Cancer Res 26:2556–2564. (PMID: 321700287654718) ; Puré E, Cuff CA (2001) A crucial role for CD44 in inflammation. Trends Mol Med 7(5):213–221. (PMID: 11325633) ; Qian H, Le Blanc K, Sigvardsson M (2012) Primary mesenchymal stem and progenitor cells from bone marrow lack expression of CD44 protein. J Biol Chem 287:25795–25807. (PMID: 226541063406666) ; Riethmüller G, Johnson JP (1992) Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancers. Curr Opin Immunol 4(5):647–655. (PMID: 1418733) ; Rosenbaum MW et al (2017) Cytologic characteristics of circulating epithelioid cells in pancreatic disease. Cancer Cytopathol 125:332–340. (PMID: 28257167) ; Roxburgh CSD, McMillan DC (2014) Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer 110(6):1409–1412. (PMID: 245488673960633) ; Schott DS et al (2021) Influence of adjuvant radiotherapy on circulating epithelial tumor cells and circulating cancer stem cells in primary non-metastatic breast cancer. Transl Oncol 14:101009. (PMID: 334534697811056) ; Schreier S, Triampo W (2020) The blood circulating rare cell population. What is it and what is it good for? Cells 9:790. (PMID: 322181497226460) ; Schreier S, Triampo W (2021a) Systemic cytology. A novel diagnostic approach for assessment of early systemic disease. Med Hypotheses 156:110682. (PMID: 34598097) ; Schreier S et al (2021b) Circulating erythroblast abnormality associated with systemic pathologies may indicate bone marrow damage. J Circ Biomark 10:14. (PMID: 346943038493595) ; Shliakhtunou YA (2021) CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study. Breast Cancer Res Treat 186(2):439–451. (PMID: 333893997990849) ; Theodoropoulos PA et al (2010) Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 288:99–106. (PMID: 19619935) ; Trochon V et al (1996) Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer 66:664–668. (PMID: 8647630) ; Williams AL et al (2020) Short-term circulating tumor cell dynamics in mouse xenograft models and implications for liquid biopsy. Front Oncol 10:2447. ; Yung S, Chan TM (2009) Intrinsic cells: mesothelial cells—central players in regulating inflammation and resolution. Perit Dial Int 29:21–27g. Contributed Indexing: Keywords: Breast cancer; CD44; Circulating rare cells; Liquid biopsy; Minimal residual disease; Systemic inflammation Substance Nomenclature: 0 (Hyaluronan Receptors) ; 0 (CD24 Antigen) ; 0 (CD44 protein, human) ; 0 (CD24 protein, human) Entry Date(s): Date Created: 20220913 Date Completed: 20230719 Latest Revision: 20230719 Update Code: 20231215 PubMed Central ID: PMC9470072

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

New inflammatory indicators for cell-based liquid biopsy: association of the circulating CD44+/CD24- non-hematopoietic rare cell phenotype with breast cancer residual disease.